SAN FRANCISCO, CA: Positive Preclinical Study Results Demonstrate Potent and Specific Anti-AML Activity for Amphivena's Proprietary T-Cell Redirecting Bispecific CD33/CD3-Targeting Antibodies; AMV-564 Being Advance ...
Gelnhausen: Gelnhausen, Germany, May 21, 2015: At the sixth International Drug-Drug Interaction Workshop more than 80 experts discussed regulatory requirements and current scientific aspects on the preclinical an ...
Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.